Table 1.
Demographics and clinical characteristics of study participants.
| Characteristic | Hair data group£ (n=398) |
|---|---|
| Age (years)¥ | 43.9 ± 8.7 |
|
| |
| BMI (kg/m2) | 28.5 ± 7.12 |
|
| |
| Height (m) ¥ | 1.61 ± 0.07 |
|
| |
| Self-reported ethnicity, n (%) | |
| White (Non-Hispanic) | 64 (16.1%) |
| African-American (Non-Hispanic) | 194 (48.7%) |
| Hispanic | 130 (32.7%) |
| Asians, Pacific Islanders and others | 10(2.51%) |
|
| |
| CrCl (n=392), n (%)¥ | |
| Normal (>90 ml/min) | 89 (22.7%) |
| Mild impairment (60–90 ml/min) | 216 (55.1%) |
| Moderate impairment (30–59 ml/min) | 79 (20.1%) |
| Severe impairment (<30 ml/min) | 8 (2.0%) |
|
| |
| EGFR* (mL/min/1.73 m2) ¥ | 91.7 ± 26.4 |
|
| |
| Self-reported adherence, n (%) | |
| >=95% | 398 (100%) |
| 75–94% | 0 (0) |
| <75% | 0 (0) |
|
| |
| HBV antigen positive (n=394), n (%) | 6 (1.3%) |
|
| |
| HCV RNA positive, n (%) | 69 (17.3%) |
|
| |
| Liver enzymes (IU) | |
| ALT | 26.9 ± 29.3 |
| AST | 29.4 ± 20.1 |
| GGT¥ | 45.3 ± 64.2 |
|
| |
| Bilirubin, total (mg/dl) | 1.7 ± 1.2 |
|
| |
| Crack use (n=394), n (%) | 18 (4.5%) |
|
| |
| Cocaine use (n=394), n (%)¥ | 3 (0.8%) |
|
| |
| Heroin use (n=394), n (%) | 5 (1.2%) |
|
| |
| Smoker, n (n=394) (%) | 160 (40.1%) |
|
| |
| Alcohol use (n=394), n (%) | |
| Abstain | 259 (65.7%) |
| >0–7 drinks/week | 121(30.7%) |
| >7–12 drinks/week | 9 (2.3%) |
| >12 drinks/week | 5 (1.3%) |
|
| |
| Drug interaction variables, n (%) | |
| Medications that Decrease ATV exposure | 170 (42.7%) |
| Antacids | 21 (5.3%) |
| Ritonavir¥ | 339 (85.2%) |
|
| |
| Not pregnant (n=397), n (%) | 394 (99.2%) |
£
Data are expressed as mean ± standard deviation except if specified otherwise (i.e. n (%)).
*
eGFR was calculated using the CKD-EPI equation.
¥
GWAS analysis adjusted for the following non-genetic predictors
Abbreviations: Alanine aminotransferase (ALT); Atazanavir (ATZ); Aspartate aminotransferase (AST); Body mass index (BMI); Creatinine clearance (CrCl); Estimated glomerular filtration rate (eGFR); Chronic kidney disease epidemiology collaboration equation (CKD-EPI); Gamma-glutamyl transferase (GGT); Hepatitis B virus (HBV); Hepatitis C virus (HCV); International units (IU).